TREND IN MORTALITY OF THE HEPATOCELLULAR CARCINOMA IN COLOMBIA, 2000-2024
Author(s)
Ismael De Jesús Yepes Barreto, MD. Gastroenterólogo-Hepatólogo1, Juan Ignacio Marín Zuluaga, MD. Hepatólogo2, Nelson R. Alvis Zakzuk, Jr., MBA3, Nelson Alvis-Guzman, MPH, PhD, MD4;
1Universidad de Cartagena, CARTAGENA, Colombia, 2Unidad de hepatología y Trasplante hepático Hospital Pablo Tobón Uribe, Medellin, Colombia, 3ALZAK Foundation, Cartagena, Colombia, 4Universidad de la Costa, Professor, Barranquilla, Colombia
1Universidad de Cartagena, CARTAGENA, Colombia, 2Unidad de hepatología y Trasplante hepático Hospital Pablo Tobón Uribe, Medellin, Colombia, 3ALZAK Foundation, Cartagena, Colombia, 4Universidad de la Costa, Professor, Barranquilla, Colombia
OBJECTIVES: to describe the mortality from hepatocellular carcinoma (HCC) in Colombia, 2000-2024.
METHODS: HCC was defined as ICD-10 codes C22. The distribution of causes by age, sex, and year was estimated. Proportional mortality rates (/100,000) were estimated. Trends in hepatocellular carcinoma mortality rate (HCMR) were analysed using Joinpoint regression to determine inflection points for temporal analysis and annual percent change (APC). Data were obtained from the national population statistics agency, DANE.
RESULTS: During the study period, there were 44,407 deaths related to HCC (0.80% of the total). Of these, 51.3% were women and 78.4% were people aged 60 and over. The mean age at death was 69.3 years (SD: 14.1) (70.1 years (SD: 14.1) for women and 68.4 years (SD: 14.1) for men). 58.5% of deaths were coded as C22.9 (malignant tumour of the liver, unspecified), 20.1% as C22.0 (liver cell carcinoma) and 16.1% as C22.1 (carcinoma of the intrahepatic bile ducts). Between 2000 and 2024, the HCMR increased from 3.49 (95% CI: 3.30-3.68) to 4.27 (95% CI: 4.09-4.45). In men, it increased from 3.33 (95% CI: 3.08-3.39) to 4.48 (95% CI: 4.22-4.74), and in women, from 3.64 (95% CI: 3.37-3.90) to 4.07 (95% CI: 3.83-4.31). The annual percentage change (APC) of the HCMR was 0.4186 (0.1641-0.6744); in men, it was 0.9382 (0.6742-1.2013), and in women, it was -0.0723 (-0.3875 to 0.246). The change in women was not significant.
CONCLUSIONS: The mortality rate related to hepatocellular carcinoma increased significantly in Colombia during this period, with no gender differences observed
METHODS: HCC was defined as ICD-10 codes C22. The distribution of causes by age, sex, and year was estimated. Proportional mortality rates (/100,000) were estimated. Trends in hepatocellular carcinoma mortality rate (HCMR) were analysed using Joinpoint regression to determine inflection points for temporal analysis and annual percent change (APC). Data were obtained from the national population statistics agency, DANE.
RESULTS: During the study period, there were 44,407 deaths related to HCC (0.80% of the total). Of these, 51.3% were women and 78.4% were people aged 60 and over. The mean age at death was 69.3 years (SD: 14.1) (70.1 years (SD: 14.1) for women and 68.4 years (SD: 14.1) for men). 58.5% of deaths were coded as C22.9 (malignant tumour of the liver, unspecified), 20.1% as C22.0 (liver cell carcinoma) and 16.1% as C22.1 (carcinoma of the intrahepatic bile ducts). Between 2000 and 2024, the HCMR increased from 3.49 (95% CI: 3.30-3.68) to 4.27 (95% CI: 4.09-4.45). In men, it increased from 3.33 (95% CI: 3.08-3.39) to 4.48 (95% CI: 4.22-4.74), and in women, from 3.64 (95% CI: 3.37-3.90) to 4.07 (95% CI: 3.83-4.31). The annual percentage change (APC) of the HCMR was 0.4186 (0.1641-0.6744); in men, it was 0.9382 (0.6742-1.2013), and in women, it was -0.0723 (-0.3875 to 0.246). The change in women was not significant.
CONCLUSIONS: The mortality rate related to hepatocellular carcinoma increased significantly in Colombia during this period, with no gender differences observed
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EPH191
Topic
Epidemiology & Public Health
Disease
SDC: Gastrointestinal Disorders